Price
$8.25
Decreased by -3.62%
Dollar volume (20D)
6.10 M
ADR%
4.95
Shares float
82.27 M
Shares short
23.49 M [28.56%]
Shares outstanding
85.06 M
Market cap
701.78 M
Beta
0.82
Price/earnings
N/A
20D range
8.20 9.80
50D range
7.26 10.20
200D range
4.93 14.44

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases in the United States.

The company's lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.

It also provides ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease.

Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer.

Anavex Life Sciences Corp. was incorporated in 2004 and is headquartered in New York, New York.

  • Quarterly earnings
  • Annual earnings
Reported date EPSChange YoY EstimateSurprise
Feb 5, 25 -0.14
Decreased by -27.27%
-0.17
Increased by +17.65%
Nov 25, 24 -0.14
Decreased by -16.67%
-0.17
Increased by +17.65%
Aug 6, 24 -0.14
Increased by 0.00%
-0.16
Increased by +12.50%
May 9, 24 -0.13
Increased by +23.53%
-0.11
Decreased by -18.18%
Feb 7, 24 -0.11
Increased by +35.29%
-0.14
Increased by +21.43%
Nov 27, 23 -0.12
Increased by +33.33%
-0.15
Increased by +20.00%
Aug 8, 23 -0.14
Increased by +12.50%
-0.17
Increased by +17.65%
May 9, 23 -0.17
Decreased by -21.43%
-0.19
Increased by +10.53%
  • Quarterly financials
  • Annual financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Dec 31, 24 0.00
Decreased by N/A%
-12.11 M
Decreased by -40.47%
Decreased by N/A%
Decreased by N/A%
Sep 30, 24 0.00
Decreased by N/A%
-11.62 M
Decreased by -14.53%
Decreased by N/A%
Decreased by N/A%
Jun 30, 24 0.00
Decreased by N/A%
-12.21 M
Decreased by -8.28%
Decreased by N/A%
Decreased by N/A%
Mar 31, 24 0.00
Decreased by N/A%
-10.55 M
Increased by +19.54%
Decreased by N/A%
Decreased by N/A%
Dec 31, 23 0.00
Decreased by N/A%
-8.62 M
Increased by +33.53%
Decreased by N/A%
Decreased by N/A%
Sep 30, 23 0.00
Decreased by N/A%
-10.15 M
Increased by +29.00%
Decreased by N/A%
Decreased by N/A%
Jun 30, 23 0.00
Decreased by N/A%
-11.28 M
Increased by +8.79%
Decreased by N/A%
Decreased by N/A%
Mar 31, 23 0.00
Decreased by N/A%
-13.11 M
Decreased by -25.57%
Decreased by N/A%
Decreased by N/A%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY